A Randomized Single Center Controlled Study of Perioperative Chemotherapy of Oxaliplatin Combined With Capecitabine (XELOX) Versus XELOX as Post-operative Chemotherapy in Advanced Gastric Adenocarcinoma With D2 Dissection

Trial Profile

A Randomized Single Center Controlled Study of Perioperative Chemotherapy of Oxaliplatin Combined With Capecitabine (XELOX) Versus XELOX as Post-operative Chemotherapy in Advanced Gastric Adenocarcinoma With D2 Dissection

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Therapeutic Use
  • Acronyms REPEAT
  • Most Recent Events

    • 14 Aug 2017 Status changed from suspended to recruiting.
    • 29 Mar 2015 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
    • 13 Dec 2013 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top